On February 7, 2018, the Food and Drug Administration (FDA) approved abiraterone acetate tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). FDA initially approved abiraterone acetate with...
Original Article: FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer
NEXT ARTICLE